Zenig Pharmaceuticals Introduces Lilly's Novel Obesity and Diabetes Treatment in Thailand
Get Ready to Tackle Obesity and Diabetes with Mounjaro®: Arriving in Thailand by End of May 2025
A game-changer is about to enter the healthcare scene in Thailand! Mounjaro® (tirzepatide), an innovative medication developed by Eli Lilly and Company for managing obesity and diabetes, will hit the Thai market by the end of May 2025. Thanks to a partnership with Zuellig Pharma, this cutting-edge treatment will be more accessible for Thais dealing with chronic illnesses like obesity and diabetes[1][2][3].
Why is everyone talking about Mounjaro®? This once-weekly prescription-only medicine promises to offer a dual solution for both conditions, all while keeping things simple with its user-friendly prefilled pen format[3]. It's available in four dosage options: 2.5 mg, 5 mg, 7.5 mg, and 10 mg, so healthcare providers can tailor treatment plans to meet individual patient needs[3].
Statistics show that obesity is a pressing problem in Thailand. As many as 48% of the country's population struggles with this issue[4]. The Ministry of Public Health considers obesity a Non-Communicable Disease (NCD) given its strong link to escalating rates of chronic conditions, particularly type 2 diabetes[4]. A staggering number - 1 in 10 Thai individuals - currently live with type 2 diabetes, impacting their physical, mental, and social well-being[4].
The introduction of Mounjaro® doesn’t just mark a milestone in the treatment of obesity and diabetes. It heralds a new era where these chronic afflictions, which can lead to severe complications such as cardiovascular disease, chronic kidney disease, diabetic retinopathy, and diabetic foot ulcers, might be manage more effectively[5]. As Sunaiyanaa Kidkasetpaisal, the General Manager of Zuellig Pharma's Commercialization division in Thailand, puts it, they're committed to expanding healthcare access for patients, and Mounjaro® is a significant step in that direction[1].
Stay tuned for more updates on this exciting development in Thailand's healthcare landscape!
Sources:
[1] Mounjaro. Prescribing Information. Eli Lilly Asia, Inc.[2] Division of Non-communicable Disease, Department of Disease Control, Ministry of Public Health.[3] Yang, T., Qi, F., Guo, F. et al. An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory. Mol Med 30, 71 (2024). https://doi.org/10.1186/s10020-024-00824-9[4] Zuellig Pharma.press. (2025). Press Release: Mounjaro® (tirzepatide) set to improve diabetes and obesity management in Thailand (prnewswire.com).[5] Centers for Disease Control and Prevention. (2025). Chronic complications of type 2 diabetes:PAGE_1_MAIN (cdc.gov).
- The upcoming arrival of Mounjaro® in Thailand's market by end of May 2025 signifies a significant shift in the country's economy, politics, and health sector, as it addresses chronic diseases like obesity and diabetes.
- With the introduction of Mounjaro®, Thailand's focus on health and wellness is expected to expand, particularly in relation to the management of chronic conditions such as type 2 diabetes.
- In light of escalating rates of obesity and diabetes in Thailand, business opportunities in the health, fitness, and nutrition sectors could potentially flourish, given the demand for weight management and holistic health solutions.
- The science behind Mounjaro®, a pioneering medication developed by Eli Lilly and Company, has the potential to revolutionize the medical-conditions sector, offering a dual solution for obesity and type 2 diabetes.
- The partnership between Eli Lilly and Company and Zuellig Pharma ensures that Mounjaro® will be more accessible in Thailand, directly impacting the economy by improving the overall health and well-being of the population.
- The successful implementation of Mounjaro® in Thailand could serve as a model for other countries striving to manage obesity and type 2 diabetes, thereby contributing to the global healthcare landscape.
